Stock Analysis tagged as

Sector - Healthcare and Social Assistance

  • Showing 101-150 of 150 items
  • <<
  • 1
  • 2
  1. Abbott Labs Joins The Separation Movement

  2. High Yielding Equities

  3. PPD Goes Private

  4. 3 Reasons To Own Lincare Holdings

  5. The 3 Highest Yielding Pharma Stocks

  6. MELA Gets A Surprising "Yes"

  7. Endo And Forest – Dumpster-Diving In Pharma

  8. R&D The Future For Life Sciences Equipment Firms

  9. When Times Are Tough, Should Investors Go Swiss?

  10. Medtronic's Healthy Growth Outlook

  11. Are Buybacks A Bad Sign?

  12. Betting On Healthcare's Growth Engine

  13. BD Healthy, But No Great Bargain

  14. CVS Still Needs to Prove Itself

  15. The Perpetual Boston Scientific Turnaround Story

  16. Teva And Mylan Show Some Value Remains In Generics

  17. Covidien's Image Starting To Change

  18. Top Dividend Stocks Owned By The Pros

  19. Top Healthcare Dividend Stocks

  20. Should Investors Circle Back To Cubist?

  21. Three Safe Sectors For The Summer

  22. Affymetrix's Downward Spiral Continues

  23. Should Biotech Investors Go Where Institutions Won't?

  24. Immucor Passes Its Last Test

  25. The Best IPOs From The First Half

  26. Top Drug Stocks

  27. Investing For Growth And Value

  28. Pleasure And Pain For Pfizer

  29. Johnson & Johnson Surrenders In Stents

  30. Lipitor: Pfizer's Loss Is Watson's Gain

  31. Should Investors Worry If Gen-Probe Doesn't Sell Out?

  32. 3 Reasons To Own Moog Inc.

  33. A Dull ASCO And The Usual Sell-Off

  34. Arena's New Data Doesn't Change Obesity Pill Outlook

  35. Medtronic Still Muddling Through

  36. Will Nestle Succeed Where Others Have Failed?

  37. Mergers In Orthopedics Could Heat Up Stocks

  38. Teva And Cephalon Solve Each Other's Problems

  39. 7 Dividend Stocks With Big Payouts

  40. Hologic Holding The Line

  41. Novo Nordisk Still One Of The Best Around

  42. Illumina Lights Up Again

  43. Can St. Jude Live Up To Newfound Expectations?

  44. J&J Beats Analyst Expections, But Not Its Rivals

  45. Despite The Noise, Abbott Still A Value

  46. GNC's Solid IPO

  47. Consolidation And Healthcare REITs

  48. Danaher Hopes To Revive Beckman Coulter

  49. Novartis Building Itself Into A One-Stop Shop

  50. MannKind And The FDA - Here We Go Again

  • Showing 101-150 of 150 items
  • <<
  • 1
  • 2
Trading Center